BC
OCUL icon

Bridgefront Capital’s Ocular Therapeutix OCUL Stock Holding History

Bridgefront Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$367K Buy
+43,351
New +$413K 0.09% 338
2021
Q3 		– Sell
-17,141
Closed -$243K – 582
2021
Q2 		$243K Buy
+17,141
New +$261K 0.09% 429

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bridgefront Capital's OCUL Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Ocular Therapeutix (OCUL) in Q1 2026: 43,351 shares worth $367K. The stake represents 0.09% of the portfolio and ranks #338 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in OCUL as recently as Q2 2021.

Bridgefront Capital first reported a position in OCUL in Q2 2021 and has held it in 2 quarters since. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Bridgefront Capital held 43,351 shares of Ocular Therapeutix worth $367K as of Q1 2026.
  • Ocular Therapeutix was a new Bridgefront Capital position in Q1 2026.
  • Ocular Therapeutix made up 0.09% of Bridgefront Capital's portfolio in Q1 2026, its #338 holding.
  • Bridgefront Capital first reported a position in Ocular Therapeutix in Q2 2021 and has held it in 2 quarters since.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.